What is Lutris Pharma?
Lutris Pharma is a clinical-stage biopharmaceutical company dedicated to improving anti-cancer therapies and patient quality of life. The company specializes in developing LUT014, a novel topical B-Raf Inhibitor designed to mitigate the dermal toxicities associated with EGFR Inhibitors and radiation therapy. By addressing side effects such as acneiform lesions and radiation dermatitis, Lutris Pharma aims to enhance patient adherence to critical oncological treatments. The company has received FDA waivers, facilitating an accelerated development pathway for its products, which are currently being evaluated in clinical trials at prominent US oncological centers.
How much funding has Lutris Pharma raised?
Lutris Pharma has raised a total of $30M across 1 funding round:
Other Financing Round
$30M
Other Financing Round (2025): $30M with participation from Columbus Venture Partners SGEIC, Pontifax, Peregrine Ventures, and aMoon
Key Investors in Lutris Pharma
Columbus Venture Partners SGEIC
Columbus Venture Partners is a venture capital firm focused on advancing biotechnology that transforms lives and generates solid returns, investing in therapeutic and industrial products through life science funds.
Pontifax
Pontifax Venture Capital specializes in groundbreaking innovations in life sciences, focusing on transformative healthcare technologies across all development stages and actively scouting disruptive ideas.
Peregrine Ventures
Peregrine Ventures is dedicated to advancing medical innovation through global strategic investments, focusing on life science companies at various stages of development and leveraging deep industry knowledge.
What's next for Lutris Pharma?
The substantial enterprise-level capital infusion positions Lutris Pharma for accelerated growth and the advancement of its clinical pipeline. This strategic backing is expected to fuel further development of LUT014 and potentially expand the company's research into other areas of supportive oncology care. With FDA waivers in hand and ongoing clinical trials, Lutris Pharma is poised to make significant strides in reducing treatment-related side effects, thereby enhancing the overall efficacy and tolerability of cancer therapies. The company's focus on patient adherence and quality of life, coupled with this recent financing, signals a strong trajectory towards market entry and broader clinical application.
See full Lutris Pharma company page
